Annovis Bio Inc (ANVS)

Feb 20, 2025

Annovis Bio to Host Patient-Centered Webcast on Key Clinical Developments - MSN

Feb 20, 2025

Feb 20, 2025

Annovis Bio stock hits 52-week low at $2.42 amid market challenges By Investing.com - Investing.com South Africa

Feb 20, 2025

Feb 19, 2025

Annovis Bio stock hits 52-week low at $2.42 amid market challenges - Investing.com

Feb 19, 2025

Feb 19, 2025

Annovis to Host Patients' Live Forum on February 27, 2025 - Quantisnow

Feb 19, 2025

Feb 19, 2025

Inside Annovis's Groundbreaking Alzheimer's Trial: CEO Opens Direct Dialogue With Patients - StockTitan

Feb 19, 2025

Feb 16, 2025

Annovis Bio stock hits 52-week low at $2.59 amid sharp decline - MSN

Feb 16, 2025

Feb 13, 2025

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.

Feb 13, 2025

Feb 12, 2025

Annovis Bio stock rating cut to hold at D. Boral Capital - MSN

Feb 12, 2025

Feb 11, 2025

Annovis Bio stock hits 52-week low at $2.59 amid sharp decline By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 09, 2025

Annovis Bio CEO to Present at Oppenheimer Healthcare Life Sciences Conference - MSN

Feb 09, 2025

Feb 09, 2025

Annovis Bio Launches Phase 3 Trial for Alzheimer’s Drug Buntanetap - MSN

Feb 09, 2025

Feb 07, 2025

Annovis Bio begins pivotal phase 3 Alzheimer's drug trial - MSN

Feb 07, 2025

Feb 07, 2025

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Feb 07, 2025

Feb 07, 2025

Annovis Bio Raises $21 Million in Public Offering to Advance Alzheimer’s Research - MSN

Feb 07, 2025

Feb 07, 2025

Annovis Bio Inc. CEO to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference on Pivotal Phase 3 Trial Progress - Nasdaq

Feb 07, 2025

Feb 07, 2025

Annovis to Present at Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - Hamilton Spectator

Feb 07, 2025

Feb 06, 2025

Annovis begins treatment of subjects in Alzheimer’s trial - Yahoo Finance

Feb 06, 2025

Feb 06, 2025

Annovis Bio begins pivotal phase 3 Alzheimer's drug trial By Investing.com - Investing.com Australia

Feb 06, 2025

Feb 06, 2025

Annovis Bio announces first patients entered Phase 3 study of buntanetap - Yahoo Finance

Feb 06, 2025

Feb 06, 2025

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire

Feb 06, 2025

Feb 06, 2025

Annovis Bio stock hits 52-week low at $4.05 amid market challenges - MSN

Feb 06, 2025

Feb 05, 2025

Annovis Bio sets terms for $21 million public offering - MSN

Feb 05, 2025

Feb 05, 2025

Annovis Bio completes $21 million stock and warrant offering - MSN

Feb 05, 2025

Feb 05, 2025

Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease - Marketscreener.com

Feb 05, 2025

Feb 05, 2025

Annovis Bio Launches Phase 3 Alzheimer’s Study - TipRanks

Feb 05, 2025

Feb 05, 2025

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease - Quantisnow

Feb 05, 2025

Feb 04, 2025

Annovis Bio completes $21 million stock and warrant offering By Investing.com - Investing.com South Africa

Feb 04, 2025

Feb 04, 2025

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - GlobeNewswire

Feb 04, 2025

Feb 04, 2025

Alzheimer's Drug Developer Annovis Secures Critical $21M Funding for Final-Stage Trial - StockTitan

Feb 04, 2025

Feb 04, 2025

Annovis Bio stock dips after pricing $21M securities offering - MSN

Feb 04, 2025

Feb 03, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Feb 03, 2025

Feb 03, 2025

Annovis Bio Prices $21 Million Public Offering; Shares Fall Sharply -February 03, 2025 at 11:56 am EST - Marketscreener.com

Feb 03, 2025